TEVA Stock: Price, Earnings History and SEC Filings
Teva Pharmaceutical Industries Limited (TEVA) last traded at $42.09, up 1.50% on the latest session and up 6.3% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.00 against an analyst estimate of $0.05, a miss of 100.0%.
$42.09 +1.50%
1 month+6.29%
52-week high$42.59
52-week low$20.11
Volume7.32M
ExchangeNYSE
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
TEVA earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 29, 2026 | $0.00 | $0.05 | -100.00% |
| Mar 2026 | Apr 29, 2026 | $0.50 | $0.49 | +2.04% |
| Dec 2025 | Jan 28, 2026 | $0.93 | $0.63 | +47.62% |
| Sep 2025 | Nov 5, 2025 | $0.75 | $0.66 | +13.64% |
TEVA beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for TEVA
SEC filing data is not available right now. You can search for TEVA on SEC EDGAR.
TEVA news
- Teva: I Still See Upside After A Massive RallyOct 31, 2026 · seekingalpha.com
- Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In DealmakingOct 31, 2026 · stocktwits.com
- Teva Stock Has More Than Doubled in a Year. Where Will It Be in 3 Years?Oct 30, 2026 · fool.com
- Teva stock in focus after BXCL501 rights dealOct 30, 2026 · ad-hoc-news.de
- Bausch Health Soars 21% on Beat-and-Raise Quarter: Core EBITDA Hits a “First Time” MilestoneOct 29, 2026 · tikr.com
- What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q3 EarningsOct 29, 2026 · finance.yahoo.com
- Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience PipelineOct 27, 2026 · finance.yahoo.com
- Zacks downgrades Teva stock to Strong Sell below yearly highOct 26, 2026 · ad-hoc-news.de
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited (TEVA) is a US-listed public company on NYSE.